Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CBX7 | O95931 | 1/20 | 0.36 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.36 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.36 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19086567 | 0.86 | SIGMAR1 (0.36) | MAPTCNR1CNR2NPC1CBX7 | |
| SCHEMBL30214700 | 0.84 | CBX7 (0.49) | NPC1CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL16932267 | 0.84 | CBX7 (0.49) | NPC1CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL19896268 | 0.80 | MAPT (0.49) | MAPTMAPK8CNR1CNR2 | |
| SCHEMBL28500980 | 0.80 | NPC1 (0.58) | NPC1CBX7CDYLCDY1; CDY1B | |
| SCHEMBL30615684 | 0.80 | NPC1 (0.58) | NPC1CBX7CDYLCDY1; CDY1B | |
| SCHEMBL29758930 | 0.80 | ESR2 (0.42) | NPC1CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL5259729 | 0.80 | DHFR (0.46) | NPC1 | |
| SCHEMBL1568526 | 0.80 | ESR2 (0.42) | NPC1CBX7CDYL2CDYLCDY1; CDY1B | |
| SCHEMBL30538022 | 0.77 | PIK3CD (0.46) | CNR1CNR2NPC1CBX7CDYL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3190104-B1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2021-10-27 | — | — | EP | disclosed |
| US-10065928-B2 | Quinolinone compound and use thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-04 | — | — | US | disclosed |
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3190104-A1 | QUINOLINONE COMPOUND AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2017-07-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247332-A1 | QUINOLINONE COMPOUND AND USE THEREOF | HIF1AN, HIF1A, EGLN2 | MAPT 4743/4885MAPK8 1637/4885CNR1 1008/4885 |
| US-10065928-B2 | Quinolinone compound and use thereof | HIF1AN, HIF1A, EGLN2 | MAPT 4743/4885MAPK8 1637/4885CNR1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.